首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1285084

全球器官晶片市場 - 2023-2030年

Global Organ-on-Chip Market - 2023-2030

出版日期: 2023年06月05日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概況

全球器官晶片市場在2022年達到1.075億美元，預計到2030年將達到7.967億美元，在2023-2030年的預測期間，預計將以29.6%的複合增長率增長。器官晶片市場趨勢顯示，由於疾病發病率的上升和研究與開發的增加，大量採用器官晶片進行藥物發現。

器官晶片市場範圍包括細分為肝臟晶片模型、肺部晶片模型、腎臟晶片模型、腫瘤模型、心臟晶片模型、定制和多器官晶片模型及其他，這增加了器官晶片的市場佔有率。器官晶片技術的主要優勢是可以創建一個詳細的人體模型，在器官或組織層面上有操作反應，從而繞過了動物模型的使用，也極大地提高了個人醫療保健的新藥研發業務。

器官晶片的全球市場正在擴大，其因素包括市場發展的不斷壯大和在藥物開發中替代動物試驗的需要，以及器官晶片在藥物設計和開發中的支持性指南和批准的存在。 2023年1月17日，CN生物創新有限公司宣布FDA和CN生物創新有限公司將第二次擴大合作關係。新的研究將使用PhysioMimix多器官系統來評估多器官MPS及其應用。

市場動態

器官晶片模型是動物試驗的替代物，推動了晶片上器官市場的增長。

除了已經被調查到的痛苦之外，實驗室中的動物被剝奪了一切真正重要的東西，它們被限制在籠子中，被社會隔離，並受到心理創傷。用於研究的有意識和有情感的生命被當作一次性的實驗室設備來對待。大部分的動物研究並沒有改善人類的健康，而且動物研究對大多數醫學發展的影響有多大也是值得懷疑的。

另外，嚴格的監管政策和法律的存在正在推動研究人員選擇替代動物試驗的方法。例如，《動物福利法》，或稱AWA，是一項聯邦法規，處理在調查機構獲得維護動物標準。這項法規禁止了大約95%的測試動物，如鳥類、老鼠、魚類、爬行動物和小鼠，對其餘動物只提供最低限度的保護。實驗室不需要報告非AWA保護的動物。

不斷增長的市場發展為製造商創造了有利可圖的機會。

在預期的期限內，全球市場的擴張正被不斷增加的市場進步所推動，包括器官晶片行業的產品發布、合作、收購和合併。例如，2022年5月，器官晶片設計公司Emulate Inc.為研究炎症性腸病的調查人員推出了一個更高的產品，其組織模型允許展示免疫細胞如何在體內被觸發和分佈。

此外，2022年4月，Valo Health公司完成了對TARA Biosystems公司的收購，該公司是一個3D心臟組織模型平台的設計者。 Valo打算將TARA的心臟組織晶片整合到一個端到端的藥物設計產品中，致力於心血管疾病的研究，由其Opal數據平台推動。同樣，在2022年9月，CiRA研究團隊開發了一個氣道晶片，利用氣道組織和血管組織的內皮細胞制定呼吸器官。

替代物的可用性將阻礙市場的增長。

市場上存在著晶片上器官的替代品，這阻礙了整個預期時間內全球市場的擴張。市場上有大量的有機體，它們具有模擬組織和器官生理的類似功能，是在預測期內器官晶片行業擴張的一個重要障礙。

例如，2023年2月，高性能生命科學產品的頂級供應商Molecular Devices, LLC.與成人幹細胞衍生器官領域的前沿企業HUB Organoids（HUB）形成合作，旨在幫助下一代3D生物學技術的持續發展，促進臨床前到臨床藥物減量的一步步變化演繹。

COVID-19影響分析

在COVID-19大流行之前，器官晶片在藥物設計和開發中的應用是有限的，但在最初階段，感染者的數量呈指數增長，特定的診斷和治療方法的不可用性要求增加研究和開發活動，這促使了器官晶片設備的採用增長。

例如，儘管動物原型和單層細胞培養物被用於發病機制的調查和COVID-19治療的設計，但生物工程器官晶片和幹細胞器官已經成為兩個前沿技術，用於創建生物模擬的體外3D（3D）組織或器官原型。

俄烏戰爭影響分析

俄羅斯-烏克蘭衝突估計對全球器官晶片市場的影響不大，因為該地區的主要市場參與者數量不多。然而，在預測期內，原材料進出口的影響預計對全球器官晶片市場的增長影響不大。

Market Overview

The Global Organ-On-Chip Market reached US$ 107.5 million in 2022 and is expected to reach US$ 796.7 million by 2030 and is expected to grow with a CAGR of 29.6% during the forecast period 2023-2030. The organ-on-chip market trends show large adoption of organ-on-chip for drug discovery owing to the rising prevalence of disorders and increasing research and development.

The organ-on-chip market scope comprises models segmented as a liver-on-chip model, lung-on-chip model, kidney-on-chip model, tumor models, heart-on-chip model, custom & multi-organ-on-chip models and others, which has increased the organ-on-chip market share. The main advantage of organ-on-a-chip technology is the facility to create a detailed human model that has operational reactions on the level of organs or tissues, thereby bypassing the usage of animal models, as well as immensely enhancing new drug discovery operations for personal healthcare.

The global market for organ-on-chip is expanding as a result of factors including the increasing market developments and the need for an alternative to animal testing in drug development and the presence of supportive guidelines and approvals for organ-on-chip in drug design and development. On January 17, 2023, CN Bio Innovations Ltd announced that the FDA and CN Bio Innovations Ltd are expanding the partnership for the second time. The new research will use the PhysioMimix Multi-organ System to assess multi-organ MPS and their applications.

Market Dynamics

Organ-On-Chip Model an Alternative to Animal Testing Drives The Growth Of The Organ-on-Chip Market.

Further to the suffering of the true investigations, animals in laboratories are denied everything realistic and crucial to them, they are restricted to empty cells, socially secluded, and psychologically traumatized. The conscious and emotional beings used in research are treated in the same manner as disposable lab equipment. The bulk of animal research does not improve human health, and it is questionable how much of an impact animal research has on most medical developments.

Also, the presence of stringent regulatory policies and laws is pushing researchers to opt for alternatives to animal testing. For instance, the Animal Welfare Act, or AWA, is a federal regulation that handles the criterion of maintenance animals acquire at investigation establishments. This regulation bans approximately 95% of the animals tested like birds, rats, fish, reptiles, and mice, and delivers only minimal protection for the rest. Labs are not needed to report non-AWA-protected animals.

Increasing Market Development Creates Lucrative Opportunities For Manufacturers.

The global market expansion in the anticipated term is being driven by the rising number of market advancements, including product launches, partnerships, acquisitions and mergers in the organ-on-chip industry. For instance, in May 2022, organ-on-a-chip designer Emulate Inc. introduced an elevated offering for investigators researching inflammatory bowel disorder with its tissue model that permits the demonstration of how immune cells are triggered and distributed in the body.

Additionally, in April 2022, Valo Health completed the acquisition of TARA Biosystems, designers of a 3D cardiac tissue modeling platform. Valo intended to integrate TARA's cardiac tissue chips into an end-to-end drug design offering strived at cardiovascular disorder, pushed by its Opal data platform. Similarly, in September 2022, the CiRA research team developed an airway-on-a-chip that enacts respiratory organs employing endothelial cells from airway tissue and vascular tissue.

Availability of Substituents Will Hamper The Growth Of The Market.

The existence of an alternative to organs-on-chips on the market is impeding the expansion of the global market throughout the anticipated time. The market's abundance of organoids, which have the similar function of simulating tissue and organ physiology, is a significant barrier to the expansion of the organ-on-chip industry over the forecast period.

For instance, in February 2023, Molecular Devices, LLC., a top provider of high-performance life science products, and HUB Organoids (HUB), the frontiers in the domain of adult stem cell-derived organoids, formed a collaboration aimed at aiding the persistent development of next-generation 3D biology technologies that facilitates a step-change deduction in pre-clinical to clinical drug attrition.

COVID-19 Impact Analysis

Before the COVID-19 pandemic, organ-on-chip was employed in drug design and development to a limited extent but during the initial period, the number of infected individuals was increasing exponentially, and the unavailability of particular diagnostic and treatments called for increased research and development activities which led to growth in the adoption of organ-on-chip devices.

For instance, although animal prototypes and monolayer cell cultures were employed for pathogenesis investigations and the design of COVID-19 treatment, bioengineered organs-on-chips, and stem cell organoids have appeared as two cutting-edge technologies utilized to create biomimetic in vitro three-dimensional (3D) tissue or organ prototypes.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a low impact on the global organ-on-chip market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global organ-on-chip market growth over the forecast period.

Segment Analysis

The global organ-on-chip market is segmented based on model, application, end user and region.

Drug Discovery From the Application Segment Accounts For 49.4% Of Market Share Owing To Rising Research And Development.

Compared to conventional 2D cell cultures, organ-on-chip platforms can be employed for high-throughput screening of drug candidates in an environment that is more physiologically realistic. Organ-on-chip platforms enable researchers to test and assess the safety and efficacy of drug candidates in a more realistic environment by simulating the microenvironment and functional characteristics of certain organs or tissues. Earlier in the drug discovery process, this can assist uncover possible lead compounds or eliminate hazardous or ineffective candidates, saving time and resources.

The pharmacokinetics (PK) of drug candidates, including their absorption, distribution, metabolism, and excretion (ADME) characteristics, can be studied using organ-on-chip platforms in a more physiologically comparable setting. In addition, almost 44,000 Americans have drug-induced liver infections (DILI). Therefore, creating a liver-on-a-chip technology would be crucial for several diagnostic and therapeutic fields, especially for creating novel treatments for long-term illnesses like hepatitis B, liver cirrhosis, and hepatocellular cancer.

Geographical Analysis

North America Accounted For Approximately 44.8% Of The Market Share Owing To The Strong Presence Of Major Players And Increasing Technological Advancements.

Manufacturers have chances to expand their operations in this region because of the rising demand for organ-on-chip for advancements in North America. The area has many producers and its rapid economic development has raised industrial production of organ-on-chips models. Using cutting-edge technologies, such as 3D bioprinting, Organovo Holdings, Inc., a company that specializes in three-dimensional (3D) biology, successfully took its first inflammatory bowel disease model toward the next stage of target discovery and validation for Crohn's disease.

Furthermore, the growing partnership, adoption and awareness initiatives for organ-on-chip are also contributing to the growth of the regional market in the forecast period. For instance, on May 19, 2021, the collaboration between InSphero AG, a leader in 3D cell-based assay technology, and Hamilton, a leading provider of automated liquid handling equipment, aims to enhance the creation and management of 3D microtissues (spheroids). These factors show the dominance of North America.

Competitive Landscape

The major global players in the organ-on-chip market include: Emulate Inc., Organovo Holdings, Mimetas B.V., AxoSim, Inc., Insphero, CN Bio Innovations Ltd, TissUse GmbH, Hesperos Inc., and Nortis, Inc. among others.

Why Purchase the Report?

To visualize the global organ-on-chip market segmentation based on model, application, end user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of organ-on-chip market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global organ-on-chip market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Model
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Organ-On-Chip Model an Alternative for Animal Testing
  - 4.1.1.2. Increasing Market Developments
- 4.1.2. Restraints
  - 4.1.2.1. Availability of Substituents
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing Government Initiatives and Investment in Drug Development and Research
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Model

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 7.1.2. Market Attractiveness Index, By Model
7.2. Liver-On-Chip Model *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Lung-On-Chip Model
7.4. Kidney-On-Chip Model
7.5. Tumor Models
7.6. Heart-On-Chip Model
7.7. Custom & Multi-Organ-On-Chip Models
7.8. Others

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Drug Discovery *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Physiological Model Development
8.4. Toxicology Research

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Pharmaceutical & Biotechnology Companies *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Academic & Research Institutes
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. The U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. The U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Italy
  - 10.3.6.5. Spain
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan

Australia

10.5.6.4. Rest of Asia-Pacific

10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Model
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. Emulate Inc. *
- 12.1.1. Company Overview
- 12.1.2. Product Portfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Mimetas B.V.
12.3. Insphero
12.4. Organovo Holdings
12.5. CN Bio Innovations Ltd
12.6. BiomimX S.r.l.
12.7. AxoSim, Inc.
12.8. Hesperos Inc.
12.9. TissUse GmbH
12.10. Nortis, Inc.

LIST NOT EXHAUSTIVE